Treatment of neovascular glaucoma by Anti VEGF injections and laser

Since the 90s, most of the choroidal melanomas have been treated by radiotherapy either with brachytherapy or external beam.Unfortunately, post radiation complications may occur and neovascular glaucoma (GNV) is one the most feared. GNV happens in almost 23% of the cases at 5 years after irradiation...

Full description

Saved in:
Bibliographic Details
Published inActa ophthalmologica (Oxford, England) Vol. 92; no. s253
Main Author MASCHI, C
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.09.2014
Wiley Subscription Services, Inc
Subjects
Diabetic retinopathy
Glaucoma
Lasers
Macular degeneration
Medical research
Melanoma
Ophthalmology
Online AccessGet full text

Cover

More Information
Summary:Since the 90s, most of the choroidal melanomas have been treated by radiotherapy either with brachytherapy or external beam.Unfortunately, post radiation complications may occur and neovascular glaucoma (GNV) is one the most feared. GNV happens in almost 23% of the cases at 5 years after irradiation, mostly for large melanomas but also for small ones. It complicates radiation retinopathy and toxic tumoral syndrome. As for diabetic retinopathy, laser photocoagulation can prevent the iris neovascularisation and glaucoma. If high pressure and secondary corneal edema are present, several authors have shown that intra‐vitreal or intra cameral injections of anti‐VEGF make iris neovessels regress and help the control of intra ocular pressure. In case of toxic tumoral syndrome, laser is ineffective and enucleation has often been necessary for intolerable pain. There is no recognized treatment for toxic tumoral syndrome: anti VEGF agents have shown good results for some patients but recent publications suggest that corticoid injections and surgical treatments may more efficient. GNV is a frequent and feared complication of ocular irradiation and its management requires several tools including laser and anti VEGF agents.
ISSN:1755-375X
1755-3768
DOI:10.1111/j.1755-3768.2014.3744.x